Ovaries stay biologically active after menopause: what the Northwestern study actually found

The end of ovulation is not the end of every biological process in the ovary. Researchers at Northwestern University and the Buck Institute for Research on Aging report that postmenopausal ovarian tissue continues to change across later decades of life. Their study, described in an October 14 report from Northwestern carried by Medical Xpress, challenges the idea that ovaries become biologically inactive after menopause.

The important distinction is between reproductive function and tissue activity. Finding changes in proteins, inflammation and tissue structure does not mean eggs are being produced again, that fertility has returned, or that normal menstrual cycles can restart. This is a study of aging tissue, not a trial of a menopause treatment.

What the researchers measured

The team examined normal ovarian tissue from 28 postmenopausal women ages 50 to 75. Using mass spectrometry, a technique that identifies and measures proteins, they analyzed 5,812 protein groups. Comparing tissue across age groups allowed them to investigate changes that continue after menopause rather than simply comparing young reproductive-age ovaries with older ones.

The news report identifies the paper as The Human Ovary Exhibits Dynamic Molecular Remodeling in the Decades Post-Menopause, published in Aging Cell. An earlier version is available on bioRxiv. The preprint link below is labeled as such; it should not be mistaken for the final journal version.

What biological activity means here

Protein patterns varied with age. The researchers reported more prominent inflammatory and tissue-remodeling processes, alongside declines in some proteins involved in maintaining tissue structure. They also described patterns associated with cellular senescence: aging or damaged cells can stop dividing while remaining active and influencing nearby tissue.

These are molecular observations. They support the conclusion that postmenopausal ovaries are not static. They do not, by themselves, establish exactly what signals reach other organs, whether those signals improve or impair health, or how much they matter for an individual patient.

The senior researchers say important questions remain

Francesca Duncan, a co-corresponding author at Northwestern, emphasized in the report that much more research is needed to determine what the ovary does after menopause and whether the observed changes are beneficial or harmful. That uncertainty is central to the finding, not a small caveat to ignore.

Co-corresponding author Birgit Schilling of the Buck Institute described potential connections between ovarian biology and other organs. Those connections are research questions; this tissue study does not establish a patient-level benefit from preserving, removing or treating ovaries.

Does this mean ovarian cancer risk has changed?

The report discusses inflammatory, fibrotic tissue environments that may be relevant to cancer biology. That is not the same as showing that the women studied developed cancer, measuring a new absolute cancer risk, or proving that the postmenopausal ovary causes cancer. A molecular pattern cannot be turned into a personal cancer prediction.

Does this change decisions about ovary removal or HRT?

No new treatment decision follows from this study alone. The researchers explicitly said their findings do not answer whether healthy ovaries should ever be removed after menopause. Decisions about surgery require the actual indication, personal and family history, inherited cancer risk where relevant, and discussion with the treating clinician.

The study also did not test whether hormone therapy reverses ovarian remodeling or improves clinical outcomes. It is not evidence for ovarian rejuvenation products, supplements, preventive surgery or changing an existing HRT prescription.

Why a valuable study still has limits

• The tissue collection involved 28 women, not a population-scale outcome study.
• Comparisons across ages are not the same as following each person through decades of ovarian aging.
• Protein measurements describe biology; they do not prove cause and effect or clinical benefit.
• The contribution of ovarian changes to whole-body health remains unresolved.

How this differs from the physiological-cliff study

A separate Nature Medicine paper published October 12 used large laboratory-test datasets to reconstruct body-wide changes around the final menstrual period. That paper came from a different research team and used a different method. One study asks what happens within ovarian tissue after menopause; the other asks how population-level physiological measures change around the transition. They should not be merged into a single claim that menopause causes inevitable deterioration.

The takeaway

Postmenopausal ovaries remain biologically active, but active does not automatically mean protective, harmful or treatable. The finding expands an important research agenda while leaving clinical decisions where they belong: with an individualized assessment and evidence appropriate to the decision being made.

Clinical review is pending. This editorial summary is educational, not individual medical advice. Do not change medication or make a surgical decision on the basis of this report.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
NPI 1609792902 · Last reviewed: October 14, 2026